Prescient Therapeutics Ltd has released a press release.
Change to exercise price of options
Filed with ASX ·
6ix hasn’t read this filing yet.
Prescient Therapeutics Limited on 6ix
Earlier from Prescient Therapeutics
- June 2016 Appendix 4C - Quarterly
- Yale Joins PTXs Phase 1b/2 AML Clinical Trial
- Replacement Entitlement Offer Prospectus
- Offer Document
- PTX Secures $7.0M Capital Raising
Later from Prescient Therapeutics
- USPTO Grants Allowances for Two PTX-200 Patents
- Appendix 4E and 2016 Annual Report
- First patient at Moffitt dosed in Phase 1b/2 breast trial
- September 2016 Appendix 4C - Quarterly
- Phase 1b/2 Ovarian Trial Commences 2nd Dose Escalation
Follow Prescient Therapeutics into a list and get an email when it puts out news.
Follow Prescient Therapeutics